News Search Results
Aug 18, 2025, 06:00 ET Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Aug. 18, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy
More news about: SystImmune, Inc.
Aug 18, 2025, 02:03 ET Investor Alert: Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Class Action
securities between March 29, 2024 and June 27, 2025. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S.
More news about: Robbins LLP
Aug 17, 2025, 20:15 ET Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
providing additional development updates moving forward." About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Aug 17, 2025, 08:01 ET GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation
the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,700 employees and has served more than 200,000 customers across 100 countries.
More news about: GenScript Biotech Corporation
Aug 15, 2025, 11:00 ET Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™
maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation
More news about: MarketsandMarkets
Aug 15, 2025, 09:00 ET Cornerstone Research Advances Seven to Senior Vice President
fraud, product liability, and intellectual property matters. In addition to healthcare, her industry expertise includes agriculture, biotechnology, financial services, technology, and transportation. She formerly headed the firm's San Francisco office.About
More news about: Cornerstone Research
Aug 15, 2025, 08:30 ET Clinical Trial Application Success: CMC and Regulatory Insights from the US to Europe, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 15, 2025, 08:00 ET Origin Agritech Hosts Industry Summit in Zhengzhou, Strengthens Distribution Network with Over 700 Partners
the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and pest resistance (Bt) traits. For further information, please visit the Company's
More news about: Origin Agritech Limited
Aug 15, 2025, 07:45 ET Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Aug. 15, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that its Board of Directors (the "Board") has adopted a Section 382 rights plan (the "Rights Plan") designed to protect
More news about: Heron Therapeutics, Inc.
Aug 15, 2025, 07:00 ET Novel Gene Therapy for ALS cleared for global trials in China and the U.S.
Aug. 15, 2025 /PRNewswire/ -- SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today that China's National
More news about: SineuGene Therapeutics
Aug 14, 2025, 20:15 ET CARsgen Therapeutics Announces 2025 Interim Results
CARsgen's share in UCARsgen will be diluted from 100% to 92%. UCARsgen is a China-based new drug discovery biotechnology company focused on allogeneic CAR T-cell therapies for the treatment of hematologic malignancies. Under the Agreements, UCARsgen has secured the
More news about: CARsgen Therapeutics
Aug 14, 2025, 16:30 ET Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution
the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the "Transaction"), the Nasdaq Stock Market LLC ("Nasdaq")
More news about: ESSA Pharma Inc.
Aug 14, 2025, 16:05 ET Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
Aug. 14, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Aug 14, 2025, 12:30 ET Biotech Stocks Rally as Oncology Market Targets $866B by 2034
ProPhase Labs, Inc. (NASDAQ: PRPH), IO Biotech, Inc. (NASDAQ: IOBT), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), and PDS Biotechnology Corporation (NASDAQ: PDSB).
More news about: Equity Insider
Aug 14, 2025, 11:00 ET Enterprise Imaging IT Market worth US$4.12 Billion by 2030 with 12.2% CAGR | MarketsandMarkets™
cardiovascular information systems (CVIS), and practice applications. The main end users of the company's solutions include hospitals, pharmaceutical firms, biotechnology companies, medical facilities, and life science research bodies. GE HealthCare serves customers in over 160 countries, conducts R&D in 18 countries,
More news about: MarketsandMarkets
Aug 14, 2025, 10:01 ET Graphene Market to Register a CAGR of 24% by 2031 - Driven by Flourishing Electronics and Energy Storage Industry | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 14, 2025, 10:01 ET Home Healthcare Market is Estimated to Reach USD 539.58 Billion by 2032 | SkyQuest Technology Consulting
grow significantly due to the high prevalence of CVD. A study published in October 2024, by the Nation Center for Biotechnology Information (NCBI) found that cardiovascular disease (CVD) accounts for about 11% of all healthcare spending in the EU, making it a significant
More news about: SkyQuest Technology
Aug 14, 2025, 10:01 ET Public Cloud Infrastructure Managed Service Market Projected to Reach USD 120 Billion by 2033, Growing at a CAGR of 8.5% - Market Research Intellect
Medical Device Manufacturing, Laboratory Applications, Food and Beverage Processing, Cosmetic Production) and End-User (Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Research Laboratories, Healthcare Institutions) and geographical regions
More news about: Market Research Intellect
Aug 14, 2025, 09:20 ET Made Scientific and New Jersey Delegates Celebrate Grand Opening of Flagship Cell Therapy Manufacturing Facility
the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors.
More news about: Made Scientific, Inc.
Aug 14, 2025, 08:36 ET Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering vision loss from retinal degenerative diseases,
More news about: Nanoscope Therapeutics
Aug 14, 2025, 08:01 ET New RoviSys Office in Puerto Rico Strengthens Regional Support for Critical Industries
expansion positions RoviSys to better support clients in the region and enhance service delivery across key industries, including pharmaceuticals and biotechnology, food and beverage, power and energy, chemicals, and aerospace. The San Juan location was selected to provide
More news about: RoviSys
Aug 14, 2025, 07:30 ET Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Aug 14, 2025, 07:00 ET Leap Therapeutics Reports Second Quarter 2025 Financial Results
Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap
More news about: Leap Therapeutics, Inc.
Aug 14, 2025, 06:59 ET The Adtech market size was valued at US$828.60 billion in 2024 and is expected to reach US$1863.91 billion by 2031; at CAGR of 14.5% during 2025-2031 | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 14, 2025, 06:56 ET Infectious Disease Therapies Market Projected to Reach $101 Billion by End of 2030
for infectious diseases. Its intranasal vaccine candidate, CoviLiv, is a live-attenuated vaccine against COVID-19.nChroma Bio: A biotechnology company advancing genetic medicines. CRMA-1001 is an epigenetic editor in development as a potential treatment for chronic hepatitis B and hepatitis
More news about: BCC Research LLC